Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Central obesity
ADR ID BADD_A06355
ADR Hierarchy
14      Metabolism and nutrition disorders
14.03      Appetite and general nutritional disorders
14.03.02      General nutritional disorders NEC
14.03.02.011      Central obesity
Description A condition of having excess fat in the abdomen. Abdominal obesity is typically defined as waist circumferences of 40 inches or more in men and 35 inches or more in women. Abdominal obesity raises the risk of developing disorders, such as diabetes, hypertension and METABOLIC SYNDROME. | Obesity due to excessive deposition of INTRA-ABDOMINAL FAT in the abdominal VISCERA and OMENTUM. [MeSH]
MedDRA Code 10065941
MeSH ID D056128; D056128; D056128
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Abdominal obesity | Truncal obesity | Central obesity | Obesity, Abdominal | Abdominal Obesities | Obesities, Abdominal | Abdominal Obesity | Central Obesity | Central Obesities | Obesities, Central | Obesity, Central | Obesity, Visceral | Visceral Obesity | Obesities, Visceral | Visceral Obesities
ADR Related Proteins
Protein Name UniProt AC TTD Target ID
Cellular retinoic acid-binding protein 1P29762Not Available
Cytochrome P450 3A43Q9HB55Not Available
Retinoic acid receptor RXR-alphaP19793T13726
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00066Alendronic acid0.000202%
BADD_D00480Clarithromycin0.000823%
BADD_D00490Clobetasol propionate0.000399%
BADD_D00491Clobetasone butyrate--
BADD_D00511Clozapine0.008407%
BADD_D00628Dexlansoprazole--
BADD_D00704Dolutegravir sodium--
BADD_D01433Methylprednisolone0.000142%
BADD_D01834Prednisone0.000040%
The 1th Page    1    Total 1 Pages